Changing Trends in Bladder Cancer: BCG, Precision Medicine, and Emerging Therapies

Tom Jayram, MD, provides insights into the latest updates on the BCG-unresponsive bladder cancer space from the LUGPA 2024 Annual Meeting. Dr. Jayram examines the role of biomarkers like FGFR and ctDNA in guiding treatment decisions and highlights how AI and genomics are being used to better understand tumor microenvironments and predict patient outcomes. Dr. Jayram also explores the ongoing shift away from cisplatin-based chemotherapy toward immunotherapy in advanced bladder cancer and considers the evolving role of immunotherapy across various treatment stages.

0:20 Trials in the BCG-Unresponsive Space
0:44 Advances in BCG-Naive Trials
1:16 Progress in Biomarkers and AI
2:15 ctDNA: A Key Biomarker in Bladder Cancer
2:48 Evolution of BCG Therapy
3:23 Moving Away from Platinum Chemotherapy
3:45 The Expanding Role of Immunotherapy